192 related articles for article (PubMed ID: 33486762)
1. Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Müller H; Elger L; Goergen H; Fuchs M; Kreissl S; Böll B; Diehl V; von Tresckow B; Borchmann P; Engert A
Br J Haematol; 2021 May; 193(3):515-519. PubMed ID: 33486762
[TBL] [Abstract][Full Text] [Related]
2. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
4. Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study.
Tao Y; Chen H; Liu D; Dai X
Leuk Res; 2021 Dec; 111():106669. PubMed ID: 34333276
[TBL] [Abstract][Full Text] [Related]
5. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
6. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
Bröckelmann PJ; Goergen H; Kohnhorst C; von Tresckow B; Moccia A; Markova J; Meissner J; Kerkhoff A; Ludwig WD; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2017 May; 35(13):1444-1450. PubMed ID: 28240973
[TBL] [Abstract][Full Text] [Related]
7. Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
Xavier AC; Armeson KE; Hill EG; Costa LJ
Cancer; 2013 Sep; 119(18):3385-92. PubMed ID: 23797978
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
10. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH
J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769
[TBL] [Abstract][Full Text] [Related]
12. Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
Dony A; Belhabri A; Bertrand Y; Sebban C; Cony-Makhoul P; Sobh M; Rogasik M; Salles G; Anglaret B; Freycon C; Corm S; Faurie P; Cornillon J; Michallet AS; Chassagne-Clément C; Berger F; Ray-Coquard IL
J Adolesc Young Adult Oncol; 2019 Dec; 8(6):684-696. PubMed ID: 31411521
[No Abstract] [Full Text] [Related]
13. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.
Yang M; Ping L; Liu W; Xie Y; Aliya ; Liu Y; Nuersulitan R; Zhu J; Wu M; Song Y
Hematology; 2019 Dec; 24(1):413-419. PubMed ID: 30922173
[TBL] [Abstract][Full Text] [Related]
15. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
Sanna G; Lorizzo K; Rotmensz N; Bagnardi V; Cinieri S; Colleoni M; Nolè F; Goldhirsch A
Ann Oncol; 2007 Feb; 18(2):288-92. PubMed ID: 17088328
[TBL] [Abstract][Full Text] [Related]
17. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
18. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
[TBL] [Abstract][Full Text] [Related]
19. Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma.
Dhir A; Epperla N; Costa LJ; Xavier AC
Front Public Health; 2023; 11():1261066. PubMed ID: 37920585
[TBL] [Abstract][Full Text] [Related]
20. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]